CourtrightPJohnsonGJ. Prevention of blindness in leprosy.London: International Centre for Eye Health, 1988.
2.
FosterA.World distribution of blindness. Community Eye Health1988; 1: 2–3.
3.
NaafsBWheateHW. The time interval between the start of anti-leprosy treatment and the development of reactions in borderline patients. Lepr Rev1978; 49: 153–7.
4.
HogewegMKiranKUSuneethaS.The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy. Lepr Rev1991; 62: 143–9.
5.
HastingsRC. Leprosy. Medicine in the Tropics.Edinburgh: Churchill Livingstone, 1985:213–15.
6.
KiranKUHogewegMSuneethaS.Treatment of recent facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Lepr Rev1991; 62: 150–4.
7.
WatsonJM. Care of the eyes, advice for patients with poor blink or closure. Partners1991; 23: 15–19.
BrowneSG. Erythema nodosum in leprosy. J Chronic Dis1963; 16: 23–30.
13.
KaracorluMACakinerTSaylanT.Corneal sensitivity and correlations between decreased sensitivity and anterior segment pathology in ocular leprosy. Br J Ophthalmol1991; 75: 117–19.
14.
ChoyceDP. Diagnosis and management of ocular leprosy. Br J Ophthalmol1969; 53: 217–23.
15.
WeerekoonL.Ocular leprosy in Ceylon. Br J Ophthalmol1969; 53: 457–65.
16.
FfytcheTJ. Role of iris changes as a cause of blindness in lepromatous leprosy. Br J Ophthalmol1981; 65: 231–9.
17.
KaracorluMACakinerTSaylanT.Influence of untreated chronic plastic iridocyclitis on intra-ocular pressure in leprosy patients. Br J Ophthalmol1991; 75: 120–2.
